Sage Group News

Opportunity to License or Acquire ES-3000, An Orphan Drug for CML and AML

Escend Therapeutics ( is based in San Diego, CA, and develops small molecule therapeutics for oncology orphan drug indications. ES-3000 is an orally bioavailable small molecule (FW ~600 Da) with a unique mechanism of action and established clinical safety. ES-3000 ablates leukemic stem cells as it reduces β-catenin by inhibition of CaMKIIγ activity. Loss of b-catenin impairs the renewal of both CML and AML stem cells. Sage represents Escend in its efforts to develop a strategic alliance for the further development of its ES-3000 oncology drug. We are pleased to attach an Executive Summary and non-confidential Information Memorandum outlining the partnering opportunity w